Studies related to Markers of airway inflammation and Fish oil

Comparable Reductions In Hyperpnoea-induced Bronchoconstriction And Markers Of Airway Inflammation After Supplementation With 6·2 And 3·1 G/d Of Long-chain N-3 PUFA In Adults With Asthma

Effect Decrease
Values Fraction of exhaled nitric oxide: high-dose decreased 21% at day 21; low-dose decreased 31% at day 21 (not statistically significantly different from high-dose group); placebo remained unchanged at day 21. Post-EVH peak increase in urinary 9-alpha, 11-beta PGF2: High-dose: decrease of 11.75 ng/mmol creatinine; low-dose: 12.86 ng/mmol creatinine; placebo: no effect.
Trial Design Randomized trial
Trial Length 2-4 Weeks
Number of Subjects 16
Sex Male
Age Range 18-29, 30-44
Body Types Overweight, Average
Notes for this study:
This was a randomized cross-over study involving 16 recreationally active, nonsmoking adult males. Eight had asthma with exercise- and hyperpnea-induced bronchoconstriction (HIB), and eight didn’t. They were randomized to various combinations of high-dose (3.7 g EPA / 2.5 g DHA daily) or lower-dose (1.8 g EPA / 1.3 g DHA daily) fish oil, or placebo for 21 days. After 21 days, respiratory function was tested after a eucapnic voluntary hyperpnea (EVH) challenge, as well as several markers of airway inflammation.

Overall, men with HIB saw similar improvements in the primary outcome of FEV1 after EVH challenge (-34% for the high-dose group, -30% for the low-dose group) with no change in the group without asthma and HIB. Markers of airway inflammation also improved to a roughly equal extent with both doses in men with asthma plus HIB.
Funding issues for this study:
Supplements & placebo (but not funding) provided by manufacturer (Croda)